Gain Therapeutics annual return on equity
2021
2022
2023
2024
2025
Gain Therapeutics Return on Equity (ROE) Growth & History (GANX)
Gain Therapeutics's return on equity was −155.66% for fiscal 2025.
View full Gain Therapeutics company overviewGain Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −155.66% | +49.30 pp |
| 2024 | 2024-12-31 | −204.95% | −63.38 pp |
| 2023 | 2023-12-31 | −141.57% | −76.05 pp |
| 2022 | 2022-12-31 | −65.52% | +2.21 pp |
| 2021 | 2021-12-31 | −67.73% | — |
Gain Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −36.96% | +85.65 pp |
| Q1 2026 | 2026-03-31 | −34.44% | +34.62 pp |
| Q4 2025 | 2025-12-31 | −37.08% | +9.30 pp |
| Q3 2025 | 2025-09-30 | −110.03% | −66.68 pp |
| Q2 2025 | 2025-06-30 | −122.61% | −42.88 pp |
| Q1 2025 | 2025-03-31 | −69.06% | −31.23 pp |
| Q4 2024 | 2024-12-31 | −46.38% | +1.07 pp |
| Q3 2024 | 2024-09-30 | −43.35% | +7.87 pp |
| Q2 2024 | 2024-06-30 | −79.73% | −21.11 pp |
| Q1 2024 | 2024-03-31 | −37.83% | −7.63 pp |
| Q4 2023 | 2023-12-31 | −47.46% | −24.95 pp |
| Q3 2023 | 2023-09-30 | −51.22% | −32.87 pp |
| Q2 2023 | 2023-06-30 | −58.62% | −41.33 pp |
| Q1 2023 | 2023-03-31 | −30.20% | −20.38 pp |
| Q4 2022 | 2022-12-31 | −22.50% | −13.61 pp |
| Q3 2022 | 2022-09-30 | −18.35% | −6.53 pp |
| Q2 2022 | 2022-06-30 | −17.28% | −9.00 pp |
| Q1 2022 | 2022-03-31 | −9.82% | −0.15 pp |
| Q4 2021 | 2021-12-31 | −8.90% | — |
| Q3 2021 | 2021-09-30 | −11.82% | — |
| Q2 2021 | 2021-06-30 | −8.29% | — |
| Q1 2021 | 2021-03-31 | −9.67% | — |
Gain Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Gain Therapeutics's return on equity decreased from −67.73% to −155.66%, a change of −87.93 percentage points. The latest reported quarter, Q2 2026, shows −36.96%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gain Therapeutics source filings ↗